The anti-VEGF and anti-HGF motifs bind with high affinity and neutralize both VEGF-A and HGF, whereas the anti-HSA modules enhance MP0250 plasma half-life and tumor penetration potentiating the drug’s pharmacokinetic ([49], NCT03136653) (Figure 2b). This evidence concerns the gene VEGFA and neoplasm.